Keosys sold to Banook Group

The global leader in medical imaging technology joins Banook Group

M & A sell side 2024, June

HealthCare

“This alliance with Banook was an obvious choice. We are two complementary players with international ambitions operating in the clinical trials market. Together, we can respond to a larger number of client requests and pool our efforts to develop our business in North America. We are delighted to embark on a new stage in our development alongside the Banook team.”

Arthur Painvin, CEO of Keosys

Banook Group becomes the European leader in technological services for clinical trials and strengthens its activities and global footprint in central imaging and eCOA (electronic Clinical Outcomes Assessments)

Cambon Partners advised Keosys on this transaction.

With this acquisition, the Banook Group becomes a European leader in technology services for clinical trials, with close to 120 employees worldwide and a direct presence in Europe (France, Germany, UK, Italy), North America (USA, Canada) and
Asia-Pacific (Australia). The Group is now a lead partner for world-renowned pharmaceutical laboratories, biotech companies and Contract Research Organizations (CROs).

Keosys is a key player in central imaging with a specialization in oncology. The company is a key partner for pharmaceutical and biotech companies in assessing the efficacy of drug candidates. Keosys centralizes and analyses medical images (CT
scans, X-rays, PET scans, MRIs, etc.), using its proprietary Clinical Trial Management System (CTMS), Imagys. Based in Nantes, the company also has an office in New York (representing more than 30% of its business) and was until now owned by the New York family office JMC Investment. All 40 employees, including the management team, will join this new growth project.